Name: Circulating Tumor Antigens and their Autoantibody Reactivity as Cancer Markers
Uploaded: 2013-05-02T00:00:00
Duration: 35 min 9 s
Description: The dynamic shedding of proteins and antigens from tumor cells offers an opportunity to develop cancer markers based on the detection of such proteins and the immune response they engender in the form of autoantibodies.

SELECTBIO

Circulating Tumor Cells 2013

The dynamic shedding of proteins and antigens from tumor cells offers an opportunity to develop cancer markers based on the detection of such proteins and the immune response they engender in the form of autoantibodies.

Circulating Tumor Antigens and their Autoantibody Reactivity as Cancer Markers

The presentation will discuss the development of a fluid phase biopsy platform to detect rare cells in human blood focusing specifically on detection of circulating tumor cells (CTCs) in patient samples.

Fluid Phase of Solid Tumors: Using CTCs as a Real Time Fluid Biopsy

A novel microfilter-based technology for CTC detection, enumeration and characterization will be discussed.  This platform incorporates useful functionalities including immunofluorescence, FISH, DNA/RNA isolation etc., allowing identification of therapeutic targets.

Novel Technology Approaches for Capture and Characterization of Circulating Tumor Cells

Mechanisms of fatal brain metastatic breast cancer (BMBC) are largely unknown.  Similarly, properties and biomarker identification of circulating tumor cells (CTCs), the “seeds” of metastasis, remain elusive.  Here we report novel strategies investigating CTCs isolated from peripheral blood mononuclear cells (PBMCs) of patients with BMBC, including the development and characterization of CTC lines.  We identified a unique BMBC CTC signature (HER2+/EGFR+/HPSE+/Notch1+/EpCAM-) by investigating CTCs that could not be captured by the FDA-approved Veridex CellSearchTM platform (EpCAM - negative CTCs). Second, we analyzed the invasive and metastatic competencies of isolated CTCs.  Established CTC lines over-expressing the BMBC signature were highly invasive and capable to form brain metastasis in xenografts.  Third, tumor cell morphologies of CTC - induced metastases closely resembled those of pathologically assessed tumors of patients whose blood was source of isolated CTCs.  Fourth, the expression of proteins of the BMBC signature was detected in CTC - induced BMBC.  Collectively, we provide first-time evidence of human CTCs isolation and long-term growth, the establishment of CTC lines, and CTC metastatic competency in the presence of a biomarker signature necessary to promote BMBC.

Circulating Tumor Antigens and their Autoantibody Reactivity as Cancer Markers

Posted by

SELECTBIO

3,919 views

|

May 2, 2013

Circulating Tumor Cells 2013

Keep up to date with all your favourite videos and channels.

Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.